Trial Profile
Study to Evaluate the Role of Inhaled Nitric Oxide (iNO) on Pulmonary Hemodynamics in Patients With Intermediate/Submassive and Massive Pulmonary Embolism (PE)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 21 May 2022
Price :
$35
*
At a glance
- Drugs Nitric oxide (Primary)
- Indications Pulmonary arterial hypertension
- Focus Pharmacodynamics; Therapeutic Use
- 11 May 2022 Planned initiation date changed from 1 Nov 2021 to 1 Jun 2021.
- 11 May 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 07 Oct 2021 Planned initiation date changed from 7 Sep 2021 to 1 Nov 2021.